• Pressemitteilung BoxID 499835

Genentech and Pfizer Share CDx Success Insights at the 4th Molecular Diagnostics for Cancer Drug Development in Boston

(PresseBox) (London, UK, ) The final agenda has been released for the 4th Molecular Diagnostics for Cancer Drug Development meeting (Boston, June 25th - 28th 2012).

The 3 day agenda features 31 expert speakers including the key project leaders of Zelboraf (Genentech) and Xalkori (Pfizer) on overcoming the scientific and commercial hurdles of targeting a drug to a specific patient subpopulation, and how they gained regulatory approval of their companion diagnostics last year.

They join oncology and diagnostics experts representing: Clovis Oncology, MD Anderson Cancer Center, Johnson & Johnson, National Cancer Institute, Astellas Pharma, Fred Hutchinson Cancer Research Center, The Biomarkers Consortium, Novartis, Daiichi-Sankyo, FDA, ImmunoGen, Bristol-Myers Squibb, Morphotek, Eisai, Bayer, Dana-Farber Cancer Institute, AVEO Pharmaceuticals, Celgene and Merck.

Visit the event website or download the brochure to see the full speaker line up and agenda.

Diese Pressemitteilungen könnten Sie auch interessieren

Enger Austausch: 30 Landkreis-Ärzte zu Gast in Asklepios Fachkliniken München-Gauting

, Medizintechnik, ASKLEPIOS Fachkliniken München-Gauting

Der Ärztliche Kreisverband Starnberg hat sich in den Asklepios Fachkliniken München-Gauting getroffen. Thema der gemeinsam mit der bayerischen...

Wunden gehören in Expertenhände

, Medizintechnik, B. Braun Melsungen AG

Mehr als 340 Mediziner und Pflegende diskutierten am 29. und 30. Januar 2015 auf dem 25. GCP-Workshop in Berlin über moderne Behandlungsmöglichke­iten...

DECTRIS Ltd. Announces New MYTHEN2 R Microstrip X-Ray Detectors for OEM use in Laboratory Diffractometers

, Medizintechnik, DECTRIS Ltd.

DECTRIS Ltd. has announced its new generation of MYTHEN2 R high-performance microstrip X-ray detectors for OEM use in laboratory and portable...

Disclaimer